

Accepted Manuscript

Revised Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)

Samuel G. Armato, III, Ph.D., Anna K. Nowak, MBBS FRACP Ph.D.

PII: S1556-0864(18)30596-3

DOI: [10.1016/j.jtho.2018.04.034](https://doi.org/10.1016/j.jtho.2018.04.034)

Reference: JTHO 966

To appear in: *Journal of Thoracic Oncology*

Received Date: 5 February 2018

Revised Date: 20 March 2018

Accepted Date: 4 April 2018

Please cite this article as: Armato III SG, Nowak AK, Revised Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1), *Journal of Thoracic Oncology* (2018), doi: 10.1016/j.jtho.2018.04.034.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Revised Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)

Samuel G. Armato III, Ph.D.¹

Anna K. Nowak, MBBS FRACP Ph.D.²

¹Department of Radiology, The University of Chicago, Chicago, Illinois, USA

²School of Medicine and National Centre for Asbestos Related Diseases, University of Western Australia, Perth, Western Australia and Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia

Corresponding Author:

Samuel G. Armato III, Ph.D.

Department of Radiology

The University of Chicago

5841 South Maryland Ave., MC 2026

Chicago, IL, USA 60637

s-armato@uchicago.edu

Key words: mesothelioma, tumor measurement, tumor response assessment, modified RECIST

DISCLOSURES: Dr. Nowak reports personal fees from Boehringer Ingelheim, personal fees from Roche Products, grants from Astra Zeneca, personal fees from Merck, personal fees from Epizyme, outside the submitted work. Dr. Armato reports personal fees from Aduro Biotech, Inc., personal fees from University of Chicago, outside the submitted work.

Download English Version:

<https://daneshyari.com/en/article/8787580>

Download Persian Version:

<https://daneshyari.com/article/8787580>

[Daneshyari.com](https://daneshyari.com)